PriceTargets.com logo

NASDAQ:KOD - Kodiak Sciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $128.64
  • Forecasted Upside: 14.58 %
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$112.27 As of 04/19/2021 06:20 PM ET
▼ -2.62 (-2.28%)
1 month | 3 months | 12 months
Get New Kodiak Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KOD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KOD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$128.64
▲ +14.58% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Kodiak Sciences in the last 3 months. The average price target is $128.64, with a high forecast of $170.00 and a low forecast of $89.00. The average price target represents a 14.58% upside from the last price of $112.27.
Hold
The current consensus among 12 polled investment analysts is to hold stock in Kodiak Sciences. This rating has held steady since January 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/27/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
7/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
10/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
1/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021Morgan StanleyLower Price TargetEqual Weight$133.00 ➝ $119.00Low
i
3/17/2021Evercore ISIInitiated CoverageOutperformN/A
i
3/15/2021Morgan StanleyBoost Price TargetEqual Weight$125.00 ➝ $133.00N/A
i
3/11/2021Evercore ISIInitiated CoverageOutperformHigh
i
3/8/2021Morgan StanleyBoost Price TargetEqual Weight$125.00 ➝ $133.00High
i
3/8/2021BarclaysReiterated RatingEqual Weight ➝ Underweight$52.00 ➝ $90.00Medium
i
3/2/2021BMO Capital MarketsLower Price TargetMarket Perform$148.00 ➝ $138.00Medium
i
3/1/2021BarclaysDowngradeEqual Weight ➝ Underweight$52.00 ➝ $90.00Low
i
2/17/2021Roth CapitalDowngradeBuy ➝ Neutral$133.00 ➝ $155.00Low
i
Rating by Z. Jallah at Roth Capital
1/25/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$145.00 ➝ $148.00High
i
12/17/2020Berenberg BankInitiated CoverageBuy$156.00Medium
i
12/15/2020UBS GroupInitiated CoverageBuy$170.00Medium
i
12/11/2020Smith Barney CitigroupInitiated CoverageNeutral$134.00High
i
12/11/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageNeutral$134.00Low
i
11/30/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$74.00 ➝ $125.00High
i
11/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$80.00 ➝ $125.00Low
i
11/13/2020BMO Capital MarketsBoost Price TargetOutperform$74.00 ➝ $145.00High
i
11/13/2020The Goldman Sachs GroupDowngradeNeutral$105.00Medium
i
11/10/2020Roth CapitalBoost Price TargetBuy$124.00 ➝ $133.00High
i
11/9/2020Roth CapitalBoost Price TargetBuy$115.00 ➝ $133.00High
i
7/28/2020SunTrust BanksLower Price TargetBuy$90.00 ➝ $89.00Low
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
5/14/2020SunTrust BanksLower Price TargetBuy$101.00 ➝ $90.00High
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
4/15/2020Morgan StanleyLower Price TargetOverweight$82.00 ➝ $80.00Low
i
3/31/2020BMO Capital MarketsInitiated CoverageOutperform$74.00High
i
3/2/2020The Goldman Sachs GroupInitiated CoverageBuy$80.00Medium
i
2/18/2020BarclaysDowngradeOverweight ➝ Equal Weight$69.00Medium
i
2/5/2020SunTrust BanksInitiated CoverageBuy$101.00High
i
1/23/2020Chardan CapitalReiterated RatingBuyHigh
i
Rating by K. Nakae at Chardan Capital
1/8/2020Roth CapitalInitiated CoverageBuy$115.00Medium
i
Rating by Z. Jallah at Roth Capital
1/3/2020HC WainwrightInitiated CoverageBuy$100.00Low
i
1/3/2020Jefferies Financial GroupInitiated CoverageBuy$100.00Low
i
12/24/2019JPMorgan Chase & Co.Initiated CoverageOverweight$82.00High
i
12/17/2019Morgan StanleyBoost Price TargetOverweight$33.00 ➝ $82.00High
i
12/2/2019Chardan CapitalReiterated RatingBuy$40.00High
i
Rating by Gbola Amusa at Chardan Capital
11/13/2019Chardan CapitalReiterated RatingBuy$40.00High
i
Rating by Gbola Amusa at Chardan Capital
10/15/2019Chardan CapitalBoost Price TargetBuy$22.50 ➝ $35.00High
i
6/13/2019Chardan CapitalReiterated RatingBuy$22.50Low
i
Rating by G. Amusa at Chardan Capital
2/20/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$22.50Medium
i
Rating by G. Amusa at Chardan Capital
10/29/2018BarclaysInitiated CoverageOverweight ➝ Overweight$20.00High
i
10/29/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$20.00High
i
10/29/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$14.00High
i
Rating by Derik De Bruin at Bank of America Co.
(Data available from 4/19/2016 forward)
Kodiak Sciences logo
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $112.27
$110.00
$116.91

50 Day Range

MA: $119.52
$106.20
$134.79

52 Week Range

Now: $112.27
$42.97
$171.21

Volume

140,696 shs

Average Volume

306,368 shs

Market Capitalization

$5.74 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Kodiak Sciences?

The following Wall Street research analysts have issued research reports on Kodiak Sciences in the last twelve months: Barclays PLC, Berenberg Bank, BMO Capital Markets, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Roth Capital, Smith Barney Citigroup, SunTrust Banks, Inc., The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for KOD.

What is the current price target for Kodiak Sciences?

11 Wall Street analysts have set twelve-month price targets for Kodiak Sciences in the last year. Their average twelve-month price target is $128.64, suggesting a possible upside of 14.6%. UBS Group AG has the highest price target set, predicting KOD will reach $170.00 in the next twelve months. SunTrust Banks, Inc. has the lowest price target set, forecasting a price of $89.00 for Kodiak Sciences in the next year.
View the latest price targets for KOD.

What is the current consensus analyst rating for Kodiak Sciences?

Kodiak Sciences currently has 1 sell rating, 7 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KOD, but not buy more shares or sell existing shares.
View the latest ratings for KOD.

What other companies compete with Kodiak Sciences?

Other companies that are similar to Kodiak Sciences include Novavax, Bio-Techne, Novozymes A/S, argenx, QIAGEN, Repligen, Neurocrine Biosciences, CRISPR Therapeutics, Fate Therapeutics, Acceleron Pharma, Halozyme Therapeutics, Twist Bioscience, Denali Therapeutics, Vir Biotechnology and Adaptive Biotechnologies.

How do I contact Kodiak Sciences' investor relations team?

Kodiak Sciences' physical mailing address is 2631 HANOVER STREET, PALO ALTO CA, 94304. The company's listed phone number is 650 281 0850 and its investor relations email address is [email protected] The official website for Kodiak Sciences is kodiak.com.